Lopressor injection/black box warning: Difference between revisions

Jump to navigation Jump to search
Gerald Chi (talk | contribs)
mNo edit summary
Gerald Chi (talk | contribs)
m Replaced content with "__NOTOC__ {{{{BASEPAGENAME}} }} {{CMG}} FDA Package Insert for '''{{BASEPAGENAME}}''' contains no information regarding ''Black Box Warning''."
Line 3: Line 3:
{{CMG}}
{{CMG}}


{| style="border: 3px solid #696969;"
FDA Package Insert for '''{{BASEPAGENAME}}''' contains no information regarding ''Black Box Warning''.
| style="background: #000000; border: 0px; padding: 20px 20px; width: 800px;" |
<center>
<font color="#F8F8FF" style="font-weight: bold;">WARNING</font>
</center>
 
<center>
<font color="#F8F8FF" size="1" style="font-style: italic;">See full prescribing information for complete boxed warning.</font>
</center>
 
<font color="#F8F8FF" style="font-weight: bold;">
''[[Ischemic heart disease|{{fontcolor|#FF0000|Ischemic Heart Disease:}}]]'' Following abrupt cessation of therapy with certain beta-blocking agents, exacerbations of angina pectoris and, in some cases, myocardial infarction have occurred. When discontinuing chronically administered Lopressor, particularly in patients with ischemic heart disease, the dosage should be gradually reduced over a period of 1-2 weeks and the patient should be carefully monitored. If angina markedly worsens or acute coronary insufficiency develops, Lopressor administration should be reinstated promptly, at least temporarily, and other measures appropriate for the management of unstable angina should be taken. Patients should be warned against interruption or discontinuation of therapy without the physician’s advice. Because coronary artery disease is common and may be unrecognized, it may be prudent not to discontinue Lopressor therapy abruptly even in patients treated only for hypertension.
</font>|}

Revision as of 01:57, 21 March 2014